Cipla said that following USFDA inspection, the company's manufacturing facility in Bommasandra, Bangalore has received the EIR, indicating closure of the inspection.
The announcement was made after market hours yesterday, 8 May 2020. Shares of Cipla rose 0.42% to close at Rs 591.85 on 8 May 2020.
Cipla said that following the inspection by the United States Food and Drug Administration (USFDA) at active pharmaceutical ingredient (API) manufacturing facility in Bommasandra, Bangalore from 20 January 2020 to 24 January 2020, the company has received the Establishment Inspection Report (EIR), indicating closure of the inspection.
Cipla manufactures and sells pharmaceutical and personal care products. The Company offers active pharmaceutical ingredients, and formulations in therapeutic areas, such as allergy, analgesic, anti malarial, anti-infectives, cardiology, dermatology and cosmeceuticals, diabetology, gastroenterology, steroids, iron chelators, nutritional products.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
